Evaxion Q3 2026 slides: oncology pivot backed by 75% response rate

Evaxion Biotech (EVAX) reported a $3.5M net loss in Q3 2026, focusing on oncology after a strategic shift. Its EVX-01 cancer vaccine showed a 75% response rate in trials. Shares traded at $2.50, with a market cap of $23M. The company has a cash runway through 2027.

Original reporting
Published Nov 19, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 3:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EVAX
Bullish
medium confidence
Mentioned
$EVAX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The article combines (1) a stated oncology pivot, (2) detailed EVX-01 clinical efficacy and safety metrics, and (3) balance-sheet runway extension via ATM funding. This mix can drive near-term sentiment and trading interest, but the lack of revenue and continued dilution risk remain key counterweights.

02

Market read

Traders get a fresh catalyst from the company’s Q3 update: oncology refocus plus specific EVX-01 efficacy, immunology precision, and cash runway commentary.

03

What to watch

The update emphasizes no product revenue and ongoing cash burn, with reliance on ATM equity raises after quarter-end, which can pressure valuation even with strong immunology correlations.

Relevance 7/10Novelty 6/10Timing: today’s Q3 2026 strategic update and clinical-data recap

Background

Evaxion Biotech (NASDAQ:EVAX) delivered a Q3 2026 strategic and business update on Nov. 19, 2026, shifting internal resources from infectious disease toward oncology cancer vaccine development.

Company-level read

Ticker impact

$EVAXBullishMedium confidence
Context

Evaxion’s Q3 2026 update details a strategic oncology pivot and reports EVX-01 phase 1/2 results with a 75% objective response rate.

Expected impact

Likely upward bias on biotech risk appetite, tempered by concerns about ongoing cash burn and limited near-term revenue.

Evidence & confidence

The article provides specific trial efficacy and safety metrics plus cash runway extension, which can re-rate probability of success. However, it also highlights net losses, no product revenue, and reliance on ATM funding, which can limit valuation expansion.

Market effects

Reinforces investor focus on AI-enabled immuno-oncology platforms and personalized cancer vaccine response durability, potentially influencing read-across sentiment for similar pre-commercial biotech models.

Limited direct regional spillover; primarily impacts US small-cap biotech risk sentiment.

ESMO/SITC conference-linked data can affect global immuno-oncology narrative, but the company-specific scale is small.

Counterpoint

High response-rate claims in early-stage personalized vaccine studies may not translate into later-phase efficacy, so the market may fade the news if follow-on endpoints or manufacturing scalability are questioned.

Key entities

  • Evaxion Biotech

    NASDAQ-listed biotech pivoting to oncology and presenting EVX-01 phase 1/2 response and immunology precision data.

  • EVX-01

    Personalized melanoma vaccine with reported 75% objective response rate and 25% complete response rate in phase 1/2.

  • Merck

    Referenced as the infectious disease out-licensing partner for EVX-B3.

  • EVX-04

    Off-the-shelf DNA vaccine targeting AML via ERV antigens, advancing toward clinical development.

Related articles

$EVAXMed

Evaxion announces strategy and business update and third quarter 2026 financial results

Evaxion A/S (EVAX) announced a strategic refocus on immuno-oncology, prioritizing its AI-Immunology platform for cancer vaccine development. Key updates include advancing EVX-04 and EVX-05, expanding EVX-01's potential, and presenting new clinical data. The company reported a Q3 2026 net loss of $3.5 million and extended its cash runway to late 2027. Evaxion also won the 2026 Prix Galien Award for AI-Immunology.

$EVAXMed

Evaxion A/S (EVAX): Financial results for Q3 2026

Evaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces strategy and business update and third quarter 2026 financial results COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunolog

$EVAXMedAI 8/10

Evaxion Reports Strong Immune Responses in EVX-01 Phase 2 Data

Evaxion Biotech (EVAX) reported phase 2 data showing its cancer vaccine EVX-01 generated immune responses in advanced melanoma patients. The company's AI-Immunology predictions aligned with observed T-cell activity. Analysts have a buy rating with a $14.00 price target, but Spark's AI Analyst rates it neutral due to financial constraints and technical risks.

$EVAXMedAI 8/10

Evaxion: New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

$EVAXMedAI 9/10

Evaxion presents phase 2 cancer vaccine biomarker data at SITC

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.